Baseline patient characteristics
| Baseline cohort N=994 | Follow-up patients N=534 | Non-FU patients N=460 | |
|---|---|---|---|
| Age (years)* | 59±10 | 58±9 | 60±11 |
| Male gender, n (%) | 784 (79) | 426 (80) | 358 (78) |
| Body mass index (kg/m2)* | 26.9±3.8 | 26.9±3.6 | 26.8±4.1 |
| Waist circumference (cm)* | 95±11 | 95±11 | 96±12 |
| Blood pressure (mm Hg)* | |||
| Systolic | 144±22 | 142±20 | 145±23 |
| Diastolic | 83±12 | 82±11 | 83±12 |
| LDL cholesterol (mmol/L)* | 2.8±0.93 | 2.8±0.90 | 2.9±0.97 |
| HDL cholesterol (mmol/L)* | 1.30±0.38 | 1.31±0.38 | 1.28±0.37 |
| Triglycerides (mmol/L)† | 1.47 (1.09–2.07) | 1.41 (1.05–2.07) | 1.47 (1.09–2.07) |
| Glucose (mmol/L)* | 6.3±1.9 | 6.2±1.8 | 6.4±1.9 |
| HsCRP (mmol/L)† | 1.8 (0.9–3.8) | 1.6 (0.8–3.5) | 1.8 (0.9–3.8) |
| eGFR (mL/min/1.73 m2)* | 77.7±17.9 | 79.7±17.1 | 75.4±18.6 |
| Homocysteine (μmol/L)* | 14.0±6.0 | 13.5±4.9 | 14.6±7.0 |
| Prevalent type 2 diabetes, n (%) | 156 (16) | 71 (13) | 85 (19) |
| Metabolic syndrome, n (%)‡ | 369 (37) | 184 (35) | 185 (40) |
| Smoking, n (%) | |||
| Never | 170 (17) | 100 (18) | 70 (15) |
| Ever | 454 (46) | 257 (48) | 197 (43) |
| Current | 370 (37) | 177 (33) | 193 (42) |
| Pack years smoking* | 23.0±20.5 | 23.0±20.1 | 23.1±21.0 |
| History of vascular disease, n (%) | |||
| Cerebrovascular disease | 261 (26) | 144 (27) | 117 (25) |
| Coronary artery disease | 580 (58) | 325 (61) | 255 (55) |
| Peripheral artery disease | 241 (24) | 108 (20) | 133 (29) |
| Aneurysm of the abdominal aorta | 99(10) | 37 (7) | 62 (14) |
| Medication, n (%) | |||
| Platelet-aggregation inhibitors | 740 (74) | 407 (76) | 333 (72) |
| Blood pressure-lowering agents | 702 (71) | 382 (72) | 320 (70) |
| Lipid-lowering agents | 682 (69) | 388 (73) | 294 (64) |
| Oral anticoagulants | 80 (8) | 37 (7) | 43 (9) |
| White matter lesions (log%)* | −2.1 (1.1) | −2.3 (1.1) | −1.9 (1.1) |
| Brain parenchymal fraction (%)* | 79 (3) | 79 (3) | 79 (3) |
*Mean±SD.
†Median (IQR).
‡Defined according to the National Cholesterol Education Programme ATPIII-revised guidelines.
eGFR, epidermal growth factor receptor; HDL, high-density lipoprotein; HsCRP, high-sensitivity C reactive protein; LDL, low-density lipoprotein.